Beyond Conventional Therapy: Advancing Oral Treatment in Psoriasis & Melasma

Abstract

Psoriasis and melasma are chronic dermatological conditions with significant psychosocial and clinical burden. While traditional topical and systemic therapies have remained the mainstay of management for decades, limitations such as incomplete efficacy, side effect profiles, and patient adherence issues have prompted the ongoing search for novel oral therapies. This review comprehensively examines the current landscape of oral treatments in psoriasis and melasma, with a special focus on recent advances, underlying mechanisms, and guideline-driven recommendations. It aims to provide clinicians with a nuanced understanding of evolving therapeutic strategies, integrating emerging evidence to optimize patient outcomes and quality of life.

Introduction

Psoriasis and melasma represent two distinct but often challenging dermatological disorders characterized by chronicity and recurrence. Psoriasis, an immune-mediated condition, manifests as erythematous, scaly plaques and frequently involves systemic comorbidities. Melasma, primarily an acquired hypermelanosis, leads to symmetrical, hyperpigmented facial macules, significantly impacting patients' quality of life. Traditional therapies, though effective for many, can be limited by safety concerns and suboptimal long-term results. The advent of newer oral agents, driven by advances in pathophysiological understanding, has opened new avenues for disease control and symptom management. This review explores the epidemiology, pathogenesis, clinical features, diagnostic challenges, and especially the evolving oral therapeutic approaches for both conditions, with practical implications for current clinical practice.

Epidemiology / Disease Burden

Psoriasis affects approximately 2-4% of the global population, with notable geographical and ethnic variability. It is associated with substantial morbidity, including increased risk of cardiovascular disease, metabolic syndrome, and psychological comorbidities. Melasma, while less prevalent, disproportionately affects women, particularly those with Fitzpatrick skin types III-V, and is highly prevalent in regions with significant sun exposure. The psychosocial impact of both conditions is profound, frequently leading to anxiety, depression, and social withdrawal, underscoring the need for effective, sustainable treatments.

Pathophysiology

The pathogenesis of psoriasis involves a complex interplay between genetic predisposition, immune dysregulation, and environmental triggers. Central to its pathophysiology is the Th17/IL-23 axis, which promotes keratinocyte proliferation and chronic inflammation. In contrast, melasma is primarily driven by melanocyte hyperactivity, with contributing roles from ultraviolet (UV) radiation, hormonal influences, and genetic susceptibility. Recent research highlights the roles of vascular, inflammatory, and oxidative stress pathways in melasma, providing new mechanistic targets for systemic intervention.

Risk Factors

Psoriasis risk factors include family history, smoking, obesity, chronic stress, and certain medications (e.g., beta-blockers, lithium). Melasma is associated with female sex, pregnancy, oral contraceptive use, thyroid dysfunction, and exposure to UV light or visible light. Genetic factors play a role in both conditions, influencing susceptibility and clinical phenotype.

Clinical Features

Psoriasis typically presents as well-demarcated, erythematous plaques with silvery scales, most frequently on the extensor surfaces, scalp, and lower back. Subtypes include plaque, guttate, pustular, and erythrodermic psoriasis. Melasma manifests as symmetrical, irregularly bordered brown-to-gray macules and patches, most commonly on the malar, centrofacial, or mandibular regions. Both conditions can be exacerbated by external triggers, leading to significant cosmetic and functional impairment.

Diagnosis

Diagnosis of psoriasis is primarily clinical, supported by histopathology in atypical cases. Tools such as the Psoriasis Area and Severity Index (PASI) aid in grading disease severity. Melasma is diagnosed based on clinical appearance and Wood's lamp examination, with dermoscopy and reflectance confocal microscopy providing additional diagnostic clarity. Biopsy is reserved for atypical or recalcitrant cases to exclude other causes of hyperpigmentation.

Treatment & Management

Conventional therapy for psoriasis includes topical corticosteroids, vitamin D analogs, phototherapy, and systemic agents such as methotrexate, cyclosporine, and acitretin. For melasma, first-line management emphasizes strict photoprotection and topical agents, including hydroquinone, retinoids, and triple combination creams. However, long-term use of these agents can be limited by cutaneous side effects and tachyphylaxis. Systemic therapies have classically been reserved for refractory cases or extensive disease, but recent advancements have expanded their role.

Recent Advances / Emerging Therapies

The development of targeted oral therapies marks a paradigm shift in the management of both psoriasis and melasma. In psoriasis, oral small molecules such as apremilast, a phosphodiesterase-4 (PDE4) inhibitor, have demonstrated efficacy in moderate-to-severe disease with favorable safety profiles, particularly in patients ineligible for biologic therapy. Janus kinase (JAK) inhibitors (e.g., tofacitinib, deucravacitinib) are also gaining traction, offering oral alternatives with rapid onset and broad immunomodulatory effects. For melasma, emerging oral agents include tranexamic acid, an antifibrinolytic with demonstrated efficacy in reducing pigmentation via inhibition of the plasminogen-plasmin pathway and attenuation of melanocyte activity. Oral antioxidants, such as Polypodium leucotomos extract and glutathione, have shown promise in small trials, highlighting the role of systemic oxidative stress in disease pathogenesis. Combination regimens and patient-specific pharmacogenomic approaches are under investigation.

Guideline Recommendations

Recent international guidelines endorse the use of oral apremilast for moderate psoriasis, particularly in cases of intolerance or contraindication to traditional systemic agents. JAK inhibitors are recommended in selected patients, with careful monitoring for adverse events, including infections and thromboembolic risk. For melasma, consensus guidelines support oral tranexamic acid as adjunctive therapy in refractory disease, with attention to contraindications such as thromboembolic disorders. The importance of patient education, adherence to photoprotection, and regular monitoring for systemic side effects is emphasized across both conditions.

Conclusion

The landscape of oral therapy in psoriasis and melasma is rapidly evolving, driven by advances in molecular understanding and targeted drug development. While conventional therapies remain foundational, emerging oral agents provide new options for patients with refractory or extensive disease, offering improved efficacy, tolerability, and convenience. Clinicians should remain abreast of evolving evidence and guideline updates to optimize therapeutic outcomes, balancing efficacy with safety considerations in individualized patient care. Ongoing research and long-term real-world studies will further clarify the role of novel oral treatments in the comprehensive management of these challenging dermatological disorders.